A multivariable prediction model combining 18F-PSMA PET/CT and mpMRI for clinically significant prostate cancer: development and validation - Summary - MDSpire
Advertisement
A multivariable prediction model combining 18F-PSMA PET/CT and mpMRI for clinically significant prostate cancer: development and validation
To develop and validate a multivariable model combining clinical and imaging parameters to predict clinically significant prostate cancer (csPCa), which is crucial for effective treatment decisions.
Key Findings:
Final model retained 3 predictors: PRIMARY score, PI-RADS score, and PSAD.
Training AUC was 0.916 (95% CI: [insert CI]), sensitivity at Youden Index cutoff (≥84%) was 79.3%, specificity was 76.6%.
Sensitivity reached 96.0% at the recommended screening cutoff (≥46%).
AUC in internal test set was 0.914 (95% CI: [insert CI]) and 0.837 (95% CI: [insert CI]) in temporal validation.
Interpretation:
The multivariable model provides accurate risk stratification for csPCa, aiding in optimizing biopsy decisions and potentially reducing unnecessary procedures.
Limitations:
Study conducted at a single institution, which may limit generalizability to broader populations.
Potential selection bias due to inclusion criteria, which may affect the applicability of findings.
Conclusion:
The model integrating 18F-PSMA PET/CT and mpMRI parameters enhances pre-biopsy risk stratification for csPCa, potentially improving clinical decision-making.
